Glucagon-like polypeptide agonists in type 2 diabetes mellitus: Efficacy and tolerability, a balance

Therapeutic Advances in Endocrinology and Metabolism

Volumn 6, Issue 3, 2015, Pages 109-134

  Tella, Sri Harsha ^a   Rendell, Marc S ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Association of Diabetes Investigators   (United States)

Author keywords

albiglutide; dulaglutide; exenatide; liraglutide; lixisenatide

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; APOLIPOPROTEIN; BIPHASIC INSULIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EXENDIN 4; FATTY ACID; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LIRAGLUTIDE; LIXISENATIDE; LONG ACTING INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL;

AREA UNDER THE CURVE; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED RELEASE FORMULATION; DIARRHEA; DRUG APPROVAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; LIPID METABOLISM; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTOLIC BLOOD PRESSURE; VOMITING; WEIGHT CHANGE; WEIGHT REDUCTION;

EID: 84930588033     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018815580257     Document Type: Review

References (110)

1. Ahrén B. Gautier J. Berria R. Stager W. Aronson R. Bailey C. (2014 a) Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16: 861–868.
2. Ahrén B. Leguizamo Dimas A. Miossec P. Saubadu S. Aronson R. (2013) Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 36: 2543–2550.
3. Ahrén B. Stewart M. Cirkel D. Yang F. Perry C. Johnson S. et al. (2014 b) HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care 37:2141–2148.
4. Amblee A. (2014) Dulaglutide for the treatment of type 2 diabetes. Drugs Today 50: 277–289.
5. Arnolds S. Dellweg S. Clair J. Dain M. Nauck M. Rave K. et al. (2010) Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 33: 1509–1515.
6. Astrup A. Carraro R. Finer N. Harper A. Kunesova M. Lean M. et al. (2012) NN8022–1807 investigators safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes 36: 843–854.
7. Ban K. Noyan-Ashraf H. Hoefer J. Bolz S. Drucker D.J. Husain M. (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor dependent and independent pathways. Circulation 117: 2340–2350.
8. Barnett A. Burger J. Johns D. Brodows R. Kendall D. Roberts A. et al. (2007) Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 29: 2333–2348.
9. Bergenstal R. Wysham C. MacConell L. Malloy J. Walsh B. Yan P. et al. (2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376: 431–439.
10. Best J. Hoogwerf B. Herman W. Pelletier E. Smith D. Wenten M. et al. (2010) Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the GLP-1 receptor agonist exenatide twice daily or other glucose lowering therapies: a retrospective analysis of the LifeLinkTM database. Diabetes Care 34: 90–95.
11. Blevins T. Pullman J. Malloy J. Yah P. Taylor K. Schulteis C. et al. (2011) DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 96: 1301–1310.
12. Bolli G. Munteanu M. Dotsenko S. Niemoeller E. Boka G. Wu Y. et al. (2014) Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med 31 (2): 176–184.
13. Brubaker P. Drucker D. (2004) Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145: 2653–2659.
14. Bunck M. Cornér A. Eliasson B. Heine R. Shaginian R. Taskinen M. et al. (2011) Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34: 2041–2047.
15. Bunck M. Corner A. Eliasson B. Heine R. Shaginian R. Wu Y. et al. (2010) One year treatment with exenatide versus insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 212: 223–229.
16. Buse J. Bergenstal R. Glass L. Heilmann C. Lewis M. Kwan A. et al. (2011 a) Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 154: 103–112.
17. Buse J. Garber A. Rosenstock J. Schmidt W. Brett J. Videbæk N. et al. (2011 b) Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab 96: 1695–1702.
18. Buse J. Henry R. Han J. Kim D. Fineman M. Baron A. (2004) Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628–2635.
19. Buse J. Nauck M. Forst T. Sheu W. Shenouda S. Heilmann C. et al. (2013) Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381:117–124.
20. Buse J. Rosenstock J. Sesti G. Schmidt W. Montanya E. Brett J. et al. (2009) LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39–47.
21. Buse J. Vilsbøll T. Thurman J. Blevins T. Langbakke I. Bøttcher S. et al. (2014) NN9068–3912 (DUAL-II) Trial Investigators: contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care 37: 2926–2933.
22. Bush M. Matthews J. de Boever E. Dobbins R. Hodge R. Walker S. et al. (2009) Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide 1 mimetic, in healthy subjects. Diabetes Obes Metab 11:498–505.
23. Buteau J. (2008) GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab 34(Suppl. 2): S73–S77.
24. Charbonnel B. Bertolini M. Tinahones F. Domingo M. Davies M. (2014) Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J Diabetes Complications 28: 880–886.
25. Dalle S. Burcelin R. Gourdy P. (2013) Specific actions of GLP-1 receptor agonists and DPP 4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes. Cell Signal 25: 570–579.
26. Davies M. Donnelly R. Barnett A. Jones S. Nicolay C. Kilcoyne A. (2009) Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 11: 1153–1162.
27. de Fronzo R. Okerson T. Viswanathan P. Guan X. Holcombe J. MacConell L. (2008) Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 24: 2943–2952.
28. de Fronzo R. Triplitt C. Qu Y. Lewis M. Maggs D. Glass L. (2010) Effects of exenatide plus rosiglitazone on β-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care 33: 951–957.
29. de Rosa G. Maffioli P. Salvadeo S. Ferrari I. Ragonesi P. Querci F. et al. (2010) Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther 12: 233–240.
30. de Rosa G. Putignano P. Bossi A. Bonaventura A. Querci F. Franzetti I. et al. (2011) Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 666: 251–256.
31. Diamant M. Nauck M. Shaginian R. Malone J. Cleall S. Reaney M. et al. (2014); 4B Study Group. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 37: 2763–2773.
32. Diamant M. van Gaal L. Stranks S. Northrup J. Cao D. Taylor K. et al. (2010) Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375: 2234–2243.
33. Distiller R. Ruus P. on behalf of the ACT 6011 Study Group (2008) Pharmacokinetics and pharmacodynamics of a new GLP-1 agonist AVE 0010 in type 2 diabetes patients. Diabetes 58: A154–A155.
34. Drucker D. (2006) The biology of incretin hormones. Cell Metab 3: 153–165.
35. Drucker D. Buse J. Taylor K. Kendall D. Trautmann M. Zhuang D. et al. DURATION-1 Study Group (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372: 1240–1250.
36. Dungan K. Povedano S. Forst T. (2014) Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 384: 1349–1357.
37. Egan A. Blind E. Dunder K. de Graeff P. Hummer B. Bourcier T. et al. (2014) Pancreatic safety of incretin-based drugs – FDA and EMA assessment. N Engl J Med 370: 794–797.
38. Elashoff M. Matveyenko A. Gier B. Elashoff R. Butler P. (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141: 150–156.
39. Eli Lilly and Company (2014) Trulicity: US prescribing information. Available at: http://pi.lilly.com/us/Trulicity-uspi.pdf (accessed 30 September 2014).
40. European Medicines Agency (2009) Assessment report for Victoza. Doc. Ref. EMEA/379172/2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001026/WC500050016.pdf (accessed 23 March 2015).
41. European Medicines Agency (2012) European Public Assessment Report: lyxumia. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002445/WC500140449.pdf (accessed 29 March 2015).
42. European Medicines Agency (2015) News and Events: Saxenda recommended for approval in weight management in adults. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/01/news_detail_002255.jspandmid=WC0b01ac058004d5c1 (accessed 31 January 2015).
43. Ferdinand K. White W. Calhoun D. Lonn E. Sager P. Brunelle R. et al. (2014) Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 64: 731–737.
44. Fonseca V. Alvarado-Ruiz R. Raccah D. Boka G. Miossec P. Gerich J. (2012) Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 35 (6): 1225–31.
45. Fonseca V. DeVries J. Bain S. (2011) Liraglutide improves the profile of lipid and cardiovascular risk biomarkers from baseline. Presented at: 21st World Diabetes Congress of the International Diabetes Federation; 4–8 December; Dubai, United Arab Emirates.
46. Gallwitz B. Guzman J. Dotta F. Guerci B. Simó R. Basson B. et al. (2012) Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 379: 2270–2278.
47. Garber A. Henry R. Ratner R. LEAD-3 (Mono) Study Group (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373: 473–481.
48. Gautier J. Fetita S. Sobngwi E. Salaün-Martin C. (2005) Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 31: 233–242.
49. Gier B. Butler P. Lai C. Kirakossian D. DeNicola M. Yeh M. (2012) Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab 97: 121–131.
50. Giorgino F. Benroubi M. Sun J. (2014) Efficacy and safety of once weekly dulaglutide versus insulin glargine in combination with metformin and glimepiride in type 2 diabetes patients (AWARD-2) [abstract no. 38]. Diabetologia 57(Suppl. 1): S22.
51. Gough S. Bode B. Woo V. Rodbard H. Linjawi S. Poulsen P. et al. NN9068–3697 (DUAL-I) trial investigators (2014) Efficacy and safety of a fixed-ratio combination of *insulin degludec*and*liraglutide*(IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2: 885–893.
52. Hegedüs L. Moses A. Zdravkovic M. Le Thi T. Daniels G. (2011) GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 96: 853–860.
53. Heine R. van Gaal L. Johns D. Mihm M. Widel M. Brodows R. et al. (2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143: 559–569.
54. Henry R. Klein E. Malloy J. Griffin P. Zhou M. Iqbal N. (2014) DURATION-1 estension: efficacy and tolerability of exenatide once weekly over 6 years in patients with T2DM. 74th American Diabetes Association Session; San Francisco, CA; 13–17 June 2014. Poster #964-P. Available at: http://ada.scientificposters.com/epsView.cm (accessed 29 January 2015).
55. Holst J. Christensen M. Lund A. de Heier J. Svendsen B. Kielgast U. et al. (2011) Regulation of glucagon secretion by incretins. Diabetes Obes Metab 13(Suppl. 1): 89–94.
56. Home P. Shamanna P. Stewart M. Yang F. Miller M. Perry C. et al. (2015) 52 week efficacy of albiglutide versus placebo and versus pioglitazone in patients with type 2 diabetes currently taking metformin and glimepiride. Diabetes Obes Metab 17: 179–187.
57. Jendle J. Blonde L. Rosenstock J. (2014) Better glycaemic control and less weight gain with once weekly dulaglutide versus bedtime insulin glargine, both combined with thrice daily lispro, in type 2 diabetes (AWARD-4). Diabetologia 57(Suppl. 1): S23–S24.
58. Jimenez-Solem E. Rasmussen M. Christensen M. Knop F. (2010) Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr Opin Mol Ther 12: 790–797.
59. Kapitza C. Forst T. Coester H. Poitiers F. Ruus P. Hincelin-Méry A. (2013) Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab 15: 642–649.
60. Kendall D. Riddle M. Rosenstock J. Zhuang D. Kim D. Fineman M. et al. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083–1091.
61. Knudsen L. Madsen L. Andersen S. (2010) Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151: 1473–1486.
62. Lean M. Carraro R. Finer N. Hartvig H. Lindegaard M. Rössner S. et al. (2014) Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes 38 (5): 689–97.
63. Leiter L. Carr M. Stewart M. Jones-Leone A. Scott R. Yang F. et al. (2014) Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care 37 (10): 2723–30.
64. Levin P. Mersey J. Zhou S. Bromberger L. (2012) Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus. Endocr Pract 18: 17–25.
65. Liu Y. Ruus P. (2009) Pharmacokinetics and safety of the GLP-1 agonist AVE 0010 in patients with renal impairment. Abstract 557-P. Presented at the 69th Scientific Sessions of the American Diabetes Association; 5–9 June 2009; New Orleans, LA, USA.
66. Liu J. Wang G. Jia Y. Xu Y. (2012) GLP-1 receptor agonists and non-alcoholic fatty liver disease. Diabetes Metab J 36: 262–267.
67. MacConell L. Walsh B. Li Y. Pencek R. Maggs D. (2013): Exenatide once weekly: sustained improvement in glycemic control and weight loss through 3 years. Diabetes Metab Syndro Obes 6: 31–41.
68. Marre M. Shaw J. Brandle M. Bebakar W. Kamaruddin N. Strand J. et al. (2009) LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 26: 268–278.
69. Mathieu C. Rodbard H. Cariou B. Handelsman Y. Philis-Tsimikas A. Ocampo Francisco A. et al. (2014) BEGIN: VICTOZA ADD-ON (NN1250–3948) Study Group. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab 16: 636–644.
70. Matthews J. Stewart M. de Boever E. Dobbins R. Hodge R. Walker S. et al. Albiglutide Study Group (2008) Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 93: 4810–4817.
71. Meece J. (2009) Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog. Pharmacotherapy 29: 33S–42S.
72. Monami M. Dicembrini I. Nardini C. Fiordelli I. Mannucci E. (2014) Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16: 38–47.
73. Moretto T. Milton D. Ridge T. Macconell L. Okerson T. Wolka A. et al. (2008) Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30: 1448–1460.
74. Nathanson D. Ullman B. Löfström U. Hedman A. Frick M. Sjöholm A. et al. (2012) Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 55: 926–935.
75. Nauck M. Frid A. Hermansen K. Shah N. Tankova T. Mitha I. et al. (2009) LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32: 84–90.
76. Nauck M. Meier J. (2011) Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells? Nat Rev Endocrinol 7: 193–195.
77. Nauck M. Duran S. Kim D. Johns D. Northrup J. Festa A. et al. (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50 (2): 259–67.
78. Nauck M. Verdari I. Deacon C. Holst J. Meier J. (2011) Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54: 10–18.
79. Nauck M. Weinstock R. Umpierrez G. Guerci B. Skrivanek Z. Milicevic Z. et al. (2014) Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 37: 2149–2158.
80. Nayak U. Govindan J. Baskar V. Kalupahana D. Singh B. (2010) Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 103: 687–694.
81. Neumiller J. Campbell R. (2009) Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother 43: 1433–1444.
82. Nielsen L. Young A. Parkes D. (2004) Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117: 77–88.
83. Norris S. Lee N. Thakurta S. Chan B. (2009) Exenatide efficacy and safety: a systematic review. Diabet Med 26: 837–846.
84. Petersen A. Christensen M. (2013) Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes Metab Syndr Obes 6: 217–231.
85. Pinget M. Goldenberg R. Niemoeller E. Muehlen-Bartmer I. Guo H. Aronson R. et al. (2013) Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab 15: 1000–1007.
86. Pratley R. Nauck M. Bailey T. Montanya E. Cuddihy R. Filetti S. et al. (2010) 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375: 1447–1456.
87. Pratley R. Nauck M. Barnett A. Feinglos M. Ovalle F. Harman-Boehm I. et al. (2014) Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (Harmony 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2: 289–297.
88. Ratner R. Han J. Nicewarner D. Yushmanova I. Hoogwerf B. Shen L. (2011) Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 10: 22.
89. Rendell M. Perkins C. Scott R. Ye J. Stewart M. Carr M. et al. (2014) Harmony 2 3 year results: albiglutide monotherapy in drug-näive patients with T2DM. Diabetes 63: A245–A246.
90. Reusch J. Stewart M. Perkins C. Ye J. Perry C. Cirkel D. et al. (2014) Efficacy and safety of once weekly GLP-1 receptor agonist albiglutide (HARMONY 1): 52 week primary endpoint results from a randomized, double-blind, placebo controlled, trial in patients with type 2 diabetes mellitus not controlled on pioglitazone ± metformin. Diabetes Obes Metab 16: 1257–1264.
91. Riddle M. Aronson R. Home P. Marre M. Niemoeller E. Miossec P. et al. (2013 a) Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 36: 2489–2496.
92. Riddle M. Forst T. Aronson R. (2013 b) Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo1). Diabetes Care 36: 2497–2503.
93. Robinson L. Holt T. Rees K. Randeva 1 H. O'Hare J. (2013) Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 3: e001986
94. Rosenstock J. Fonseca V. Gross J. Ratner R. Ahrén B. Chow F. et al. (2014) Harmony 6 Study Group. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 37: 2317–2325.
95. Rosenstock J. Raccah D. Korányi L. Maffei L. Boka G. Miossec P. et al. (2013) Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 236: 2945–2951.
96. Russell-Jones D. Cuddihy R. Hanefeld M. Kumar A. González J. Chan M. et al. (2012) DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 35: 252–258.
97. Russell-Jones D. Vaag A. Schmitz O. Sethi B. Lalic N. Antic S. et al. (2009) Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide versus insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52: 2046–2055.
98. Schwartz E. Koska J. Mullin M. Syoufi I. Schwenke D. Reaven P. et al. (2010), Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 212: 217–222.
99. Seino Y. Min K. Niemoeller E. Takami A. EFC 10887 GETGOAL-L Asia Study Investigators (2012) Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 14: 910–917.
100. Trujillo J. Nuffer W. (2014) Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother 48: 1494-1501.
101. Umpierrez G. Tofé Povedano S. Pérez Manghi F. Shurzinske L. Pechtner V. (2014) Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 37: 2168–2176.
102. US Food and Drug Administration (2009) Victoza (R) (liraglutide injection): human relevance of rodent thyroid C-cell tumors. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/Committees%20MeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM151129.pdf (accessed 5 October 2010).
103. US Food and Drug Administration (2014) FDA approves trulicity to treat type 2 diabetes [media release]. 18 September 2014. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm415180.htm (accessed 29 March 2015).
104. Vilsbøll T. Christensen M. Junker A. Knop F. Gluud L. (2012) Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Br Med J 344: d7771.
105. Weissman P. Carr M. Ye J. Cirkel D. Stewart M. Perry C. et al. (2014) HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia 57: 2475–2484.
106. Wysham C. Blevins T. Arakaki R. Colon G. Garcia P. Atisso C. et al. (2014) Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1. Diabetes Care 37: 2159–2167.
107. Young M. Wald J. Matthews J. Yang F. Reinhardt R. (2014) Effect of renal impairment on the pharmacokinetics, efficacy, and safety of Albiglutide. Postgrad Med 126: 35–46.
108. Yu Pan C. Han P. Liu X. Yan S. Feng P. Zhou Z. et al. (2014) Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia). Diabetes Metab Res Rev 30 (8): 726–35.
109. Zinman B. Gerich J. Buse J. Lewin A. Schwartz S. Raskin P. et al. (2009) LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32: 1224–1230.
110. Zinman B. Hoogwerf B. Duran G. Milton D. Giaconia J. Kim D. et al. (2007) The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 146: 477–485.